On October 5, 2017, the Patent Trial and Appeal Board (“Board”) issued a final written decision in an inter partes review proceeding...
PTAB Decisions
-
-
Abraxis Bioscience, developer of cancer drug Abraxane®, filed suit against Actavis in April of 2016 following its receipt of notice that...
-
Post-grant review (PGR) is the least common post-issuance trial proceeding before the Patent Trial and Appeal Board (PTAB). Only 1% of...
-
In an effort to combat pharmaceutical patent holders, several companies are now filing petitions for post-grant review on the theory that...
-
Two IPRs (IPR2016-00663 and IPR2016-00669) filed on patents asserted against Microsoft in district court have ended with victory for the...
-
In Coalition for Affordable Drugs VIII, LLC, v. The Trustees of the University of Pennsylvania, No. IPR2015-01835, Paper No. 56 (P.T.A.B....
-
Final Written Decisions were entered on March 7, 2017 in 6 IPRs brought by Qualcomm Inc. against ParkerVision, Inc (IPR2015-01828, -01829,...